Abstract
Regional chemotherapy, and particularly hepatic arterial chemotherapy, has had a resurgence of interest in the recent past because of the development of improved technology in the form of the implanted infusion pump. The history of this form of chemotherapy, however, over the past 2 decades has consistently demonstrated response rates which are superior to standard systemic chemotherapy and in fact hepatic arterial chemotherapy is effective in 25%–60% of patients not responding to the standard systemic delivery. The rationale for regional delivery relates to maximizing the dose delivery to the tumor and because of hepatic extraction minimizing host toxicity in spite of the maximal doses. However, in addition to the regional delivery of drug, there is another important distinction from standard chemotherapy, namely the infusion schedule.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
. Ansfield F, Klotz J, Nealon T, Ramirez G, Minton J, Hill G, Wilson W, Davis H, Cornell G (1977) A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. Cancer 39: 34–40
. Lavin P, Mittelman A, Douglas H, Engstrom P, Klaassen D (1980) Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An Eastern Cooperative Oncology Group Report. Cancer 46: 1536–1543
. Engstrom PF, Maclntyre JM, Mittelman A, Klaassen DJ (1984) Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. Am J Clin Oncol (CCT) 7: 313–318
. Windschitl H, Scott M, Schutt A, McCormack G, Everson L, Cullinan S, Gerstner J, Krook J, Laurie J, Shreck R, Marschke R, Pfeifle D (1983) Randomized phase II studies in advanced colorectal carcinoma: North Central Cancer Treatment Group Study. Cancer Treat Rep 67 (11): 1001–1008
. Engstrom PF, Maclntyre JM, Douglass HO, Muggia F, Mittelman A (1982) Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer 49: 1555–1560
. Presant CA, Denes AE, Liu C, Bartolucci AA (1984) Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine. Cancer 53: 2610–2614.
. Reitemeier RJ, Moertel CG (1962) Comparison of rapid and slow intravenous administration of 5-fluorouracil in treating patients with advanced carcinoma of the large intestine. Cancer Chemother Rep 25: 87–89
. Moertel CG, Reitemeier RI, Hahn RG (1967) A controlled comparison of 5-fluoro-2’-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion. Cancer Res 27: 549–552
. Moertel CG, Schutt AJ, Reitemeier RI, Hahn RG (1972) A comparison of 5-fluorouracil administered by slow infusion and rapid injection. Cancer Res 32: 2717–2719
. Seifert P, Baker LH, Reed ML, Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36: 123–128
. Kish J, Ensley J, Weaver A, Jacobs J, Cummings G, Al-Sarraf M (1984) Superior response rate with 96 h 5-fluorouracil (5-FU) infusion vs 5-FU bolus combined with cis-platinum (CDDP) in a randomized trial for recurrent and advanced squamous head and neck cancer (HNC). Proc ASCO 3: 695
. Shah A, MacDonald WC, Gudauskas GA, Sullivan B (1984) Weekly 48-hour 5-fluorouracil (5-FU) intravenous infusion in advanced colorectal cancer. Proc ASCO 3: 454
. Hartman HA, Kessinger A, Lemon HM, Foley JF (1979) Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma. J Surg Oncol 11: 227–238
. Lokich J, Bothe A, Fine N, Perri J (1981) Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48: 2565–2568
. Lokich J, Sonneborn H, Paul S, Zipoli T (1983) Phase I study of continous venous infusion of floxuridine (5-FUdR) chemotherapy. Cancer Treat Rep 67: 791–793
. Lokich J, Moore C (1984) Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Int Med 101 (6): 798
. Leichman L, Seydel HG, Steiger Z (1984) Pre-operative adjuvant therapy for squamous cell cancer (SCC) of the esophagus: SWOG and RTOG clinical Trials. Proc ASCO 3: 575
. Leichman C, Leichman L, Migro N, Considine B, Vaitkevicius VK, Baker L (1984) Cancer of the anal canal: curative therapy without surgery. Proc ASCO 3: 529
. Grage TB, Vassilopoulos PP, Shingleton WW, Jubert AV, Elias EG, Aust JB, Moss SE (1978) Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: a Central Oncology Group Study. Surgery 86: 550–555
. Kemeny N, Daly J, Oderman P, Chun H, Petroni G, Geller N (1984) Randomized study of intrahepatic vs systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Proc ASCO 3: 551
. Stagg R, Friedman M, Lewis B, Ignoffo R, Goodnight J, Viele C, Hohn D (1984) Current status of NCOG randomized trial of continuous intraarterial (IA) versus intravenous (IV) floxuridine (FUDR) in patients with colorectal carcinoma metastatic to the liver. Proc ASCO 3: 577
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Lokich, J.J. (1986). Systemic Infusional Chemotherapy for Liver Metastasis: An Improved Schedule for 5-Fluorouracil. In: Herfarth, C., Schlag, P., Hohenberger, P. (eds) Therapeutic Strategies in Primary and Metastatic Liver Cancer. Recent Results in Cancer Research, vol 100. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-82635-1_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-82635-1_17
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-82637-5
Online ISBN: 978-3-642-82635-1
eBook Packages: Springer Book Archive